Drug-induced interstitial lung disease (ILD) and pneumonitis are adverse events linked to multiple therapeutic options used in the treatment of breast cancer. Prompt recognition is crucial, but the non-specific nature of symptoms presents challenges for timely and accurate diagnosis. Join us for a dynamic multidisciplinary discussion featuring experts in breast cancer oncology, radiology, and emergency medicine along with a real-world patient perspective on ILD/pneumonitis. Take home the lessons with a downloadable pocket guide to assist in assessing risk factors, evaluating presenting signs and symptoms to aid in accurate diagnosis, and recommended management for patients who develop ILD/pneumonitis.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/critical-clues-identifying-managing-interstitial-lung-disease-patients-breast
- Start Date: 2025-02-17 06:00:00
- End Date: 2025-02-17 06:00:00
- Credit Details: IPCE Credits: 1.0 hours
AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 59000.0 - Is Kind Support: False Source: Daiichi Sankyo, Inc. - Amount: 16000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest